Related Experiment Video
Updated: Apr 21, 2026
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac
Shujun Zhao1, Jiwei Zhang1, Yansha Zhao1
1Department of Cardiovascular Medicine, Affiliated Hospital of Hebei University Baoding 071000, Hebei, China.
Insights
Metoprolol-spironolactone combination therapy significantly improves cardiac function in patients with coronary heart disease and heart failure. This combined treatment offers superior benefits over spironolactone alone, enhancing overall patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease (CHD) and heart failure (HF) often coexist, presenting complex treatment challenges.
- Optimizing cardiac function is crucial for managing patients with concurrent CHD and HF.
Purpose of the Study:
- To evaluate the efficacy of metoprolol-spironolactone combination therapy in treating patients with CHD and concurrent HF.
- To assess the impact of this combination on cardiac function and related biomarkers.
Main Methods:
- A randomized controlled trial involving 100 patients with CHD + HF.
- Comparison of metoprolol-spironolactone combination therapy versus spironolactone monotherapy.
- Assessment of cardiac function parameters (LVESd, LVEDd, LVEF), BNP, oxidative stress markers (SOD, MDA), inflammation, hemodynamics, and clinical outcomes.
Main Results:
- The combination therapy group showed significant improvements in left ventricular dimensions (LVESd, LVEDd) and ejection fraction (LVEF).
- Reduced levels of B-type natriuretic peptide (BNP), malondialdehyde (MDA), and inflammatory cytokines were observed with combination therapy.
- Enhanced cardiac index, cardiac output, and a higher clinical efficacy rate were noted in the research group, alongside a lower adverse event rate.
Conclusions:
- Metoprolol-spironolactone combination therapy is highly effective for treating CHD + HF patients.
- This combination significantly improves cardiac function and clinical outcomes, suggesting its potential for widespread clinical adoption.
Objective:
This study intended to clarify the role of metoprolol-spironolactone combination in treating coronary heart disease (CHD) with concurrent heart failure (HF), focusing on its impact on cardiac function.
Methods:
A total of 100 CHD + HF patients were selected, including 50 cases in the control group treated with spironolactone and 50 cases in the research group given metoprolol + spironolactone. Cardiac function (left ventricular end-systolic diameter [LVESd], left ventricular end-diastolic diameter [LVEDd], left ventricular ejection fraction [LVEF]), cardiac function classification, serum brain natriuretic peptide (BNP), oxidative stress (superoxide dismutase [SOD], malondialdehyde [MDA]), inflammation, hemodynamics (cardiac index/output), effectiveness, and safety were analyzed.
Results:
The combination therapy induced a more evident reduction in LVESd, LVEDd, BNP, MDA, and two inflammatory cytokines than spironolactone alone, as well as a greater rise in LVEF, SOD, cardiac index, and cardiac output. The research group also showed superior improvements in cardiac function classification and clinical efficacy, as well as a lower overall adverse effect rate.
Conclusion:
Metoprolol-spironolactone combination is remarkably effective in treating CHD + HF and significantly improve patients' cardiac function, which merits clinical popularization.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inotropic Agents
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers